# US 2023/0265207 A1 · T cell-antigen coupler with y182t mutation and methods of uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265207 A1
- Document ID: US20230265207A1
- Status: Published application
- Kind: A1
- Application number: 18/188,318
- Filed: 2023-03-22
- Published: 2023-08-24
- Earliest claimed: 2017-10-12
- Assignees: McMaster University
- Applicants: McMaster University
- Inventors: Christopher W. Helsen; Jonathan Bramson; Anna Dvorkin-Gheva; Galina F. Denisova; Ksenia Bezverbnaya; Kenneth Anthony Mwawasi
- Web page: https://patentgrep.com/patent/US20230265207A1

## CPC

- C07K 16/3061: {Blood cells}
- C07K 16/32: against translation products of oncogenes
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/385: Haptens or antigens, bound to carriers
- A61P 35/00: Antineoplastic agents
- C07K 14/525: Tumour necrosis factor [TNF]
- C07K 14/70503: {Immunoglobulin superfamily}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70514: {CD4}
- C07K 14/70517: {CD8}
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/2818: {against CD28 or CD152}
- A61K 35/00: Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 2039/505: {comprising antibodies}
- C07K 2317/31: multispecific
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2318/20: Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A trifunctional molecule comprising a target-specific ligand, a ligand that binds a protein associated with the TCR complex and a T cell receptor signaling domain polypeptide is provided. The ligand that binds a protein associated with a TCR complex is UCHT1 with a Y182T mutation. Engineering T cells with this novel receptor engenders antigen specific activation of numerous T cell functions, including cytokine production, degranulation and cytolysis.

## Claims

### Claim 1

An engineered γδ T cell comprising an expression vector comprising a nucleic acid encoding a T Cell-Antigen Coupler (TAC) polypeptide, the TAC polypeptide comprising:
(a) an antigen-binding antibody fragment or DARPin that selectively binds a target antigen;
(b) a humanized UCHT1 (huUCHT1) polypeptide comprising the amino acid sequence of SEQ ID NO: 28; and
(c) a T cell co-receptor domain polypeptide comprising a CD4 cytosolic domain and a CD4 transmembrane domain,
wherein the TAC polypeptide is expressed by the engineered γδ T cell.

### Claim 2 (depends on 1)

The engineered γδ T cell of claim 1, wherein the antigen-binding antibody fragment or DARPin specifically binds the target antigen.

### Claim 3 (depends on 1)

The engineered γδ T cell of claim 1, wherein the T cell co-receptor domain polypeptide comprises an amino acid sequence according to SEQ ID NO: 18.

### Claim 4 (depends on 1)

The engineered γδ T cell of claim 1, wherein the antigen binding antibody fragment or DARPin binds to human epidermal growth factor receptor 2 (HER2).

### Claim 5 (depends on 1)

The engineered γδ T cell of claim 1, wherein the antigen binding antibody fragment or DARPin binds to B-cell maturation antigen (BCMA).

### Claim 6 (depends on 1)

The engineered γδ T cell of claim 1, wherein the antigen binding antibody fragment is an scFv.

### Claim 7 (depends on 1)

The engineered γδ T cell of claim 1, wherein component (a), component (b), and component (c) are fused directly to each other, or joined by at least one linker.

### Claim 8 (depends on 1)

The engineered γδ T Cell of claim 1, wherein the TAC does not comprise a co-stimulatory domain.

### Claim 9 (depends on 1)

The engineered γδ T Cell of claim 1, wherein the TAC does not comprise an activation domain.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising the engineered γδ T cell of claim 1, and a pharmaceutically acceptable excipient.

### Claim 11 (depends on 10)

A method of providing a cancer immunotherapy for treating cancer in an individual in need thereof, comprising administering to the individual the pharmaceutical composition of claim 10, wherein an antigen binding antibody fragment of the TAC polypeptide binds to a tumor antigen expressed by the cancer, wherein administration of the γδ T cell results in a reduction in cancer cells in the subject.

### Claim 12 (depends on 11)

The method of claim 11, wherein the cancer is a solid cancer.

### Claim 13 (depends on 11)

The method of claim 11, wherein the cancer is a liquid cancer.

### Claim 14 (depends on 11)

The method of claim 11, wherein the cancer is a BCMA-expressing cancer.

### Claim 15 (depends on 14)

The method of claim 14, wherein the BCMA-expressing cancer is a hematological cancer.

### Claim 16 (depends on 14)

The method of claim 14, wherein the BCMA-expressing cancer is mixed lineage leukemia (MLL), chronic lymphocytic leukemia (CLL), or acute lymphoblastic leukemia (ALL).

### Claim 17 (depends on 14)

The method of claim 14, wherein the BCMA-expressing cancer is multiple myeloma.

### Claim 18 (depends on 11)

The method of claim 11, wherein the cancer is a HER2-expressing cancer.

### Claim 19 (depends on 18)

The method of claim 18, wherein the HER2-expressing cancer is lung cancer, a breast cancer, a colon cancer, glioblastoma, ovarian cancer, stomach cancer, colorectal cancer, urothelial cancer, or endometrial cancer.
